We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

90 hedge funds and large institutions have $179M invested in Palvella Therapeutics in 2017 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 27 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 6

69% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 16

37% more capital invested

Capital invested by funds: $130M → $179M (+$48.6M)

36% more funds holding

Funds holding: 66 → 90 (+24)

0.02% more ownership

Funds ownership: 0.64% → 0.66% (+0.02%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

83% less call options, than puts

Call options by funds: $27K | Put options by funds: $156K

Holders
90
Holders Change
+24
Holders Change %
+36.36%
% of All Funds
2.04%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
30
Increased
27
Reduced
16
Closed
6
Calls
$27K
Puts
$156K
Net Calls
-$129K
Net Calls Change
-$34K

Top Buyers

1
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$2.59M
2
AL
AJO LP
Pennsylvania
+$1.7M
3
Millennium Management
Millennium Management
New York
+$1.49M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.47M
5
VIA
Vident Investment Advisory
Georgia
+$1.22M

Top Sellers

1
TCM
Tekla Capital Management
Massachusetts
-$5.09M
2
BI
BVF Inc
California
-$2.11M
3
OFM
Omega Fund Management
Massachusetts
-$1.74M
4
SFM
Sphera Funds Management
Israel
-$1.16M
5
EI
EAM Investors
California
-$348K
Name Holding Trade Value Shares
Change 		Change in
Stake
SO
26
STRS Ohio
Ohio
$851K +$597K +1,285 +1,028%
EI
27
EAM Investors
California
$797K -$348K -749 -36%
Two Sigma Investments
28
Two Sigma Investments
New York
$734K +$565K +1,216 New
FQ
29
First Quadrant
California
$670K +$39.1K +84 +8%
JP Morgan Chase
30
JP Morgan Chase
New York
$668K -$79K -170 -13%
Wells Fargo
31
Wells Fargo
California
$623K +$375K +806 +355%
Creative Planning
32
Creative Planning
Kansas
$589K +$69.7K +150 +18%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$587K +$11.6K +25 +3%
Wellington Management Group
34
Wellington Management Group
Massachusetts
$586K – – –
Mariner
35
Mariner
Kansas
$491K – – –
Baird Financial Group
36
Baird Financial Group
Wisconsin
$477K +$367K +790 New
TA
37
Teachers Advisors
New York
$460K – – –
Charles Schwab
38
Charles Schwab
California
$435K – – –
VEA
39
Virtus ETF Advisers
New York
$432K +$332K +715 New
VFA
40
Virtus Fund Advisers
Connecticut
$432K +$332K +715 New
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$425K +$15.3K +33 +5%
Squarepoint
42
Squarepoint
New York
$402K +$310K +666 New
TI
43
Trexquant Investment
Connecticut
$300K +$231K +497 New
Two Sigma Advisers
44
Two Sigma Advisers
New York
$294K +$226K +487 New
II
45
Ibex Investors
Colorado
$264K +$201K +432 New
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$259K +$199K +429 New
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$249K – – –
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$230K -$40.9K -88 -19%
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$221K -$8.37K -18 -5%
VF
50
Virtu Financial
New York
$219K -$1.86K -4 -1%
1
2
3 4

PVLA Hedge Fund Activity: Q4 2017 in Review

90 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2017, worth a combined $179M — up 37% from $130M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new PVLA positions and 6 closed out — a net gain of 24 holders — while 27 added to existing stakes and 16 trimmed.

The largest buyer was Arrowstreet Capital, opening a new position worth an estimated $2.59M. The largest seller was Tekla Capital Management, cutting an estimated $5.09M.

  • 90 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2017, up from 66 in Q3 2017.
  • Funds reported $179M of Palvella Therapeutics stock for Q4 2017, up 37% quarter-over-quarter.
  • 30 funds opened new Palvella Therapeutics positions in Q4 2017 and 6 closed out, a net change of +24 holders.
  • The largest Palvella Therapeutics buyer in Q4 2017 was Arrowstreet Capital, an estimated $2.59M added.
  • The largest Palvella Therapeutics seller in Q4 2017 was Tekla Capital Management, an estimated $5.09M sold.

Based on aggregated 13F filings for Q4 2017.